Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Lynn Dorsey Bleil net worth and biography

Lynn Bleil Biography and Net Worth

Director of Amicus Therapeutics

Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey’s worldwide Healthcare Practice before her retirement as a Senior Partner in 2013 after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Boards of Stericycle, Inc., Sonova Holding AG, and Alcon Inc. a spin-off from Novartis AG. She is also a strategic advisor to private companies Halo Neuroscience and Navigen Pharamaceuticals, and serves on the Governing Board of Intermountain’s Park City Medical Center, a non-profit healthcare organization. Her prior directorships included DST Systems, Inc. and Auspex Pharmaceuticals. Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.

Ms. Bleil serves as member of the Nominating and Governance Committee, as member of the Compensation and Leadership Development Committee and as member of the Science and Technology Committee.

What is Lynn Dorsey Bleil's net worth?: The estimated net worth of Lynn Dorsey Bleil is at least $482,472.90 as of May 25th, 2021. Ms. Bleil owns 50,310 shares of Amicus Therapeutics stock worth more than $482,473 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Bleil may own. Learn More about Lynn Dorsey Bleil's net worth.
How do I contact Lynn Dorsey Bleil?: The corporate mailing address for Ms. Bleil and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Lynn Dorsey Bleil's contact information.
Has Lynn Dorsey Bleil been buying or selling shares of Amicus Therapeutics?: Lynn Dorsey Bleil has not been actively trading shares of Amicus Therapeutics during the last quarter. Most recently, on Tuesday, May 25th, Lynn Dorsey Bleil bought 28,605 shares of Amicus Therapeutics stock. The stock was acquired at an average cost of $8.74 per share, with a total value of $250,007.70. Following the completion of the transaction, the director now directly owns 50,310 shares of the company's stock, valued at $439,709.40. Learn More on Lynn Dorsey Bleil's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 350,095 shares worth more than $4,532,405.15. The most recent insider tranaction occured on November, 6th when CEO Bradley L Campbell sold 7,901 shares worth more than $98,762.50. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 11/6/2024.

Lynn Dorsey Bleil Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/25/2021	Buy	28,605	$8.74	$250,007.70	50,310

Lynn Dorsey Bleil Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.59

$9.38

$9.68

50 Day Range

MA: $10.89

$9.52

$12.01

2 Week Range

Now: $9.59

$9.02

$14.57

Volume

1,961,452 shs

Average Volume

2,536,209 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.